Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Advancing Drug Discovery with Cutting-Edge AI & Team Synergy: Fabrice Chouraqui, CEO of Cellarity
31:40
31:40
Play later
Play later
Lists
Like
Liked
31:40
Synopsis:Step into the future of biotech as host Rahul Chaturvedi delves into an exclusive conversation with Fabrice Chouraqui, CEO of Cellarity, as he unveils the groundbreaking ways AI is revolutionizing drug discovery. Fabrice will take you behind the scenes of Cellarity’s trailblazing approach, revealing how their pioneering technology is accel…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Redefining Dementia Care: CervoMed's Bold Journey with CEO John Alam
24:38
24:38
Play later
Play later
Lists
Like
Liked
24:38
Synopsis:Get ready for an insightful conversation as host Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
From Banking to Biotech: Renée Aguiar-Lucander, CEO of Calliditas, on Rare Disease Innovation
30:51
30:51
Play later
Play later
Lists
Like
Liked
30:51
Synopsis:Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenge…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Autoimmune Innovations: Insights from Marshall Fordyce, Founder & CEO, Vera Therapeutics on Biotech
32:50
32:50
Play later
Play later
Lists
Like
Liked
32:50
Synopsis: In this engaging episode, host, Rahul Chaturvedi welcomes Marshall Fordyce, Founder and CEO of Vera Therapeutics, to discuss his transformative journey from physician to biotech entrepreneur. Marshall shares the story behind Vera Therapeutics' strategic pivot to focus on IG nephropathy and their development of atacicept, a promising B-cel…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx
50:25
50:25
Play later
Play later
Lists
Like
Liked
50:25
Synopsis:Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. S…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey
35:03
35:03
Play later
Play later
Lists
Like
Liked
35:03
Synopsis:Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Revolutionizing Proteomics: Sujal Patel, Co-Founder & CEO of Nautilus, on Drug Development
36:55
36:55
Play later
Play later
Lists
Like
Liked
36:55
Synopsis:Sujal Patel, co-founder and CEO of Nautilus Biotechnology, discusses their innovative work in proteomics and its impact on drug development. Sujal shares his transition from tech to biotech, the formation of Nautilus with Parag Mallick, and their revolutionary approach using multi-affinity probes. The conversation highlights the importance…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati
51:22
51:22
Play later
Play later
Lists
Like
Liked
51:22
Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.
28:18
28:18
Play later
Play later
Lists
Like
Liked
28:18
Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Strategic Leadership and Autoimmune Breakthroughs, Praveen Tipimeni, CEO
34:03
34:03
Play later
Play later
Lists
Like
Liked
34:03
Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach in biotech. He also discusses the importance of building a strong t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Innovative Approaches to Cancer Therapies, Robert Ang, President and CEO
30:09
30:09
Play later
Play later
Lists
Like
Liked
30:09
Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Tech-Biotech Convergence, Growth, and Global Lessons, Vik Bajaj, Co-founder and CEO
31:05
31:05
Play later
Play later
Lists
Like
Liked
31:05
Synopsis: In this episode of Biotech2050, Vik Bajaj, Co-founder and CEO of Foresite Labs, delves into the convergence of tech and biotech, hyper-growth phases in biotech companies, changes in finance and capital markets, and lessons from global healthcare systems, particularly the UK. He highlights the transformative potential of technology in biot…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Advancing and Revolutionizing Sickle Cell Treatment, Ted Love, Chair and BOD
27:00
27:00
Play later
Play later
Lists
Like
Liked
27:00
Synopsis: In this episode of Biotech2050, Dr. Ted Love, former CEO of Global Blood Therapeutics and Current Chairman of BIO, shares insights on sickle cell breakthroughs, transitioning from academia to research, navigating a tight funding environment, and protecting an innovative ecosystem to benefit patients.Biography:Dr. Ted Love is the chair of …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Demystifying Drug Discovery, Ray Stevens, CEO, Structure Therapeutics
31:57
31:57
Play later
Play later
Lists
Like
Liked
31:57
Synopsis: In this episode of the Biotech 2050 podcast, host Rahul Chaturvedi engages in a thought-provoking conversation with Ray Stevens, a prominent figure in the biotech industry who co-founded Structure Therapeutics. Ray's extensive experience and pivotal role in advancing structure-based drug discovery make him a compelling guest for biotech e…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Navigating The Evolving Landscape of Inflammation Research, Scott Megaffin, CEO, Adiso Therapeutics
27:55
27:55
Play later
Play later
Lists
Like
Liked
27:55
Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership and business management. Scott emphasizes the importance of…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Biotech's Game Changers & Revolutionizing Therapeutics, Dr. Mammen, CEO, FogPharma
50:36
50:36
Play later
Play later
Lists
Like
Liked
50:36
Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks
40:37
40:37
Play later
Play later
Lists
Like
Liked
40:37
Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis
36:41
36:41
Play later
Play later
Lists
Like
Liked
36:41
Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical com…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unlocking Genetic Medicine's Full Potential, Tuyen Ong, CEO, Ring Therapeutics
23:07
23:07
Play later
Play later
Lists
Like
Liked
23:07
Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Aging Biology and The Power of Human Data, Kristen Fortney, Co-Founder and CEO, BioAge
26:45
26:45
Play later
Play later
Lists
Like
Liked
26:45
Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the fiel…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Intersection Of Tech and Biotech, Chris Gibson, Co-Founder & CEO, Recursion
39:42
39:42
Play later
Play later
Lists
Like
Liked
39:42
Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing an MD-PhD program with a focus on merging engineering and me…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group
46:09
46:09
Play later
Play later
Lists
Like
Liked
46:09
Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making biotech more accessible to a broader audience …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT
33:34
33:34
Play later
Play later
Lists
Like
Liked
33:34
Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utili…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics
25:30
25:30
Play later
Play later
Lists
Like
Liked
25:30
Synopsis:In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics, underscores his deep understanding of the industry. He…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics
26:10
26:10
Play later
Play later
Lists
Like
Liked
26:10
Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, sh…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology
20:12
20:12
Play later
Play later
Lists
Like
Liked
20:12
Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema sinc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The promise of precision oncology, Troy Wilson, President & CEO, Kura Oncology
33:25
33:25
Play later
Play later
Lists
Like
Liked
33:25
Synopsis: Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the differences in responsibility between being a CEO and a board member. He also shares wha…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime Medicine
40:37
40:37
Play later
Play later
Lists
Like
Liked
40:37
Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Developing medicines for broad populations of cancer patients, Brett Hall, CSO, Immuneering
41:03
41:03
Play later
Play later
Lists
Like
Liked
41:03
Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Brett talks about his background in the military targeting nuclear…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Harnessing the power of microglia, Ivana Magovčević-Liebisch, President & CEO, Vigil Neuroscience
25:37
25:37
Play later
Play later
Lists
Like
Liked
25:37
Synopsis: Ivana Magovčević-Liebisch, PhD, JD, is the President and CEO of Vigil Neuroscience, a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Ivana shares…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Revolutionizing eyecare treatment, Bobak Azamian, CEO & Chairman, Tarsus Pharmaceuticals
26:37
26:37
Play later
Play later
Lists
Like
Liked
26:37
Synopsis: Bobak Azamian, MD, Ph.D., is the CEO and Chairman of Tarsus Pharmaceuticals, a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Bobby talks about his early years working in the venture capital space before founding his first company. He shares what it…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Targeting validated drivers of cancer, Nima Farzan, CEO, Kinnate Biopharma
29:46
29:46
Play later
Play later
Lists
Like
Liked
29:46
Synopsis: Nima Farzan is the CEO of Kinnate Biopharma, a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs. Having started his biotech career in the late 90s, Nima di…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Advancing bold therapies for neuronal health, Mark Litton, President & CEO, Athira Pharma
29:10
29:10
Play later
Play later
Lists
Like
Liked
29:10
Synopsis: Mark Litton, Ph.D., is the President and CEO of Athira Pharma, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration for those suffering from Alzheimer’s, Parkinson’s disease, dementia, and more. Mark talks about being a CEO for the first time and what h…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pioneering RNA editing to deliver the future of medicine, Ram Aiyar, President & CEO, Korro Bio
27:33
27:33
Play later
Play later
Lists
Like
Liked
27:33
Synopsis: Ram Aiyar, Ph.D., MBA, is the President & CEO of Korro Bio. Korro Bio harnesses the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Having founded several companies, Ram talks about some of the non-obvious differences in terms of being seni…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unlocking the technological potential of biology, Seemay Chou, Co-Founder & CEO, Arcadia Science
44:05
44:05
Play later
Play later
Lists
Like
Liked
44:05
Synopsis: Seemay Chou, Ph.D., is the Co-Founder and CEO of Arcadia Science, a research and development company leveraging the biology of emerging research organisms. Seemay sits down with Alok to discuss her move from academic science into an entrepreneurial role and her advice for others looking to make a similar transition. She talks about Arcadi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pioneering tRNA therapeutics, Michelle Werner, CEO, Alltrna & CEO-Partner, Flagship Pioneering
29:38
29:38
Play later
Play later
Lists
Like
Liked
29:38
Synopsis: Michelle Werner is the CEO of Alltrna and a CEO-Partner at Flagship Pioneering. Alltrna is the world’s first tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Breaking new ground in the treatment of fibrosis, Bernard Coulie, President & CEO, Pliant Tx
33:15
33:15
Play later
Play later
Lists
Like
Liked
33:15
Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Bernard discusses the arc of his career and shares his perspective on the European bi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming medicine through precision epigenomic control, Mahesh Karande, Pres. & CEO, Omega Tx
29:56
29:56
Play later
Play later
Lists
Like
Liked
29:56
Synopsis: Mahesh Karande is the President and CEO of Omega Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines for unprecedented control of gene regulation and cellular function. Through its OMEGA platform, the company engineers mRNA therapeutics called Omega Epige…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Catalyzing the next generation of mRNA medicines, Joseph Payne, Founder, Pres. & CEO, Arcturus Tx
29:07
29:07
Play later
Play later
Lists
Like
Liked
29:07
Synopsis: Joseph Payne is the Founder, President and CEO of Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Joseph discusses the founding story behind Arcturus and the impetus behind starting h…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Advancing muscle biology, Robert Blum, Pres. & CEO, & Fady Malik, EVP, Research & Dev., Cytokinetics
29:34
29:34
Play later
Play later
Lists
Like
Liked
29:34
Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases. Robert and Fady discuss how the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen
28:13
28:13
Play later
Play later
Lists
Like
Liked
28:13
Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases. James talks about his experience on the venture capital side and how that has influenc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Conquering new frontiers in cell therapy, Paul Lammers, CEO, Triumvira Immunologics
33:46
33:46
Play later
Play later
Lists
Like
Liked
33:46
Synopsis: Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer. A Dutch-trained biologist and physician, Paul talks about starting his caree…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-gen immunotherapies for cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma
32:42
32:42
Play later
Play later
Lists
Like
Liked
32:42
Synopsis: Andrew Scharenberg is the Co-founder and CEO of Umoja Biopharma, a company pioneering the future of immunotherapy by reprogramming T cells in vivo. Umoja’s groundbreaking integrated platform therapeutics reprogram the immune system in the patient’s body to target cancer cells and generate lasting remissions. Andrew talks about the CAR T-c…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming medicine through non-viral gene therapy, Theresa Heah, CEO, Intergalactic Tx
19:51
19:51
Play later
Play later
Lists
Like
Liked
19:51
Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to provide a p…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming diseased cells into coordinators of cure, Volker Herrmann, President & CEO, Sonata Tx
34:39
34:39
Play later
Play later
Lists
Like
Liked
34:39
Synopsis: Volker Herrmann is the President and CEO of Sonata Therapeutics, a Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Sonata’s product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Breaking barriers in rare genetic mitochondrial diseases, Greg Flesher, Pres. & CEO, Reneo
27:20
27:20
Play later
Play later
Lists
Like
Liked
27:20
Synopsis: Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases with significant unmet medical needs. Greg discusses beginning his career at Eli Lilly in the mid 1990s and how he approaches being a CEO diff…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Correcting abnormal gene expression in oncology, Adrian Gottschalk, Pres. & CEO, Foghorn Tx
31:01
31:01
Play later
Play later
Lists
Like
Liked
31:01
Synopsis: Adrian Gottschalk is the president and CEO of Foghorn Therapeutics, a clinical-stage biotechnology company pioneering a new class of medicines that treat cancers and other serious diseases by correcting abnormal gene expression. Adrian discusses his early beginnings at Biogen before joining Foghorn. He talks about the evolution of his rol…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Epigenetic therapies for organ injury & chronic liver diseases, Jim Brown, Pres. & CEO, DURECT
29:15
29:15
Play later
Play later
Lists
Like
Liked
29:15
Synopsis: Jim Brown is the President and CEO of DURECT Corporation, a biopharmaceutical company committed to transforming the treatment of acute organ injuries and chronic liver diseases by advancing novel and potentially lifesaving epigenetic therapies. Jim discusses how his early beginnings as a vet ultimately led him to the biotech industry. He …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio
29:09
29:09
Play later
Play later
Lists
Like
Liked
29:09
Synopsis: James Peyer, Ph.D., is the Founder and CEO of Cambrian Bio, a clinical-stage drug-development company focused on creating therapies to prevent and cure age-related diseases. James discusses the driving force behind his interest in aging biology and oncology, how his perspective on aging has changed over the years, his entrepreneurial jour…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Revolutionizing T-cells for solid tumor cell therapies, Gary Lee, CSO, Lyell Immunopharma
28:32
28:32
Play later
Play later
Lists
Like
Liked
28:32
Synopsis: Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+ years. He discusses how he’s observed the cell therapy space evolve over the last couple of decades…
…
continue reading